This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Zealand Pharma A/S

Drug Names(s): ZP2929

Description: ZP2929 is a dual acting agonist peptide that acts on both GLP-1 and glucagon receptors. The basis for the dual agonist concept that resulted in ZP2929 is the naturally occurring peptide hormone called oxyntomodulin. Oxyntomodulin is produced by the small intestine after meals, and is believed to exert its biological effects by activating both the GLP-1 receptor and the glucagon receptor. In humans, this hormone is believed to have multiple beneficial effects on metabolism and obesity, improving glucose tolerance and causing substantial weight loss.

GLP-1 receptor agonists have been widely demonstrated to improve glycemic control and have been linked to modest but clinically relevant weight loss in patients. Glucagon, although known to counteract GLP-1’s effect on blood glucose levels, is believed to induce fat breakdown and produce greater weight loss than GLP-1.

Deal Structure: ZP2929 was originally developed by Zealand Pharma.

Zealand Pharma and Boehringer
In June 2011, Zealand Pharma and Boehringer Ingelheim engaged in an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

As part of the agreement, Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929. Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products under the agreement.

Depending on the achievement of pre-defined development, regulatory and commercial milestones, Zealand is eligible to receive payments for ZP2929 and may also receive additional milestone payments if other products covered by the collaboration are advanced through development. Further, Zealand Pharma is entitled to tiered...See full deal structure in Biomedtracker

ZP2929 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug